Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.

Abstract: The present invention relates to a heteroaryl derivative compound and a use thereof. Since the heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR, the heteroaryl derivative can be usefully used as a therapeutic agent for EGFR-associated diseases.

Abstract: The present invention relates to host cells expressing monomeric streptavidin. The host cells according to the present invention may express streptavidin in vivo, making it possible to visualize and monitor in real time the biodistribution of cancer tissue, pre-targeted by the host cell, with a biotinylated diagnostic agent, as well as to increase the cancer-targeting efficiency of biotinylated anticancer drugs.

Abstract: The present invention relates to a monomeric streptavidin-expressing gene construct and a host cell into which a recombinant vector comprising the gene construct has been introduced. The gene construct according to the present invention, after injected in vivo through a strain, may express streptavidin, thereby making it possible not only to monitor in real time the location of the strain or a cancer tissue pre-targeted by the strain by using a biotinylated diagnostic agent, but also to increase the cancer targeting efficiency of a biotinylated anticancer agent.

Abstract: The present invention relates to aloe vera sprout concentrate or extract having cell growth promotion, antioxidant, and anti-allergy effects, and to a skin cell growth promoting, antioxidant, and anti-allergy pharmaceutical composition and functional health food or cosmetics containing the aloe vera sprout concentrate or extract as an active ingredient.